A biotechnology company has successfully manufactured the first clinical batch of a novel cell therapy designed to treat diabetic foot ulcers, a severe complication that often leads to amputation. The CYWC628 drug product, created from human fibroblast cells, is now poised to enter its first human clinical trials in the first half of 2026.
The manufacturing milestone is significant because it represents the first large-scale production of a fibroblast spheroid therapy under the strict quality standards required by the FDA. Unlike flat cell layers, these three-dimensional spheroid structures are believed to more closely mimic natural tissue and may enhance healing. The completed batch will undergo final safety and quality testing before being released for use in a planned Phase 1/2 clinical trial.
Diabetic foot ulcers are chronic wounds that affect millions globally and are notoriously difficult to heal due to poor circulation and nerve damage. Current treatment options are often limited and ineffective in the long term, making new therapeutic approaches urgently needed. The CYWC628 therapy aims to directly address the underlying biological processes of wound repair by applying concentrated, living fibroblast cells to the damaged site.
The upcoming trial will be the first to test this specific fibroblast spheroid technology in human patients. The initial phases will primarily assess the therapy's safety and tolerability while gathering early data on its efficacy in promoting wound closure. Success in these early stages would pave the way for larger trials to confirm the treatment's potential benefits.
Looking ahead, the company is preparing to initiate patient enrollment for the clinical study. If proven safe and effective, this fibroblast-based approach could offer a new, advanced treatment pathway for a debilitating condition, potentially reducing the high rates of infection and amputation associated with non-healing diabetic wounds.